RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:ITGA5-expressing tumor cells interact with Schwann cells to drive nerve growth factor-mediated immunosuppression of NK cells.
ITGA5-expressing tumor cells interact with Schwann cells to drive nerve growth factor-mediated immunosuppression of NK cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
周围神经侵犯(PNI)通过肿瘤细胞与肿瘤微环境(TME)中外周神经之间的相互作用,促进肿瘤扩散和免疫逃逸,从而使癌症治疗复杂化。
本研究探讨肿瘤细胞在 PNI 中的作用及其对神经免疫调节的影响。我们发现 ITGA5 表达升高与 PNI 之间存在强相关性,二者均因促进免疫抑制性 TME 而导致不良临床结局。
具体而言,肿瘤细胞中 ITGA5 高表达增加了神经密度并减少了NK 细胞浸润,从而促进免疫逃逸。功能实验显示,肿瘤细胞上的 ITGA5 与 SC 细胞外基质中的纤连蛋白(FN1)之间的相互作用触发 SC 重编程为修复表型,增强神经生长因子(NGF)分泌并促进肿瘤神经生成。NGF 升高通过抑制干扰素- 而抑制 NK 细胞细胞毒性,进一步支持肿瘤生长。
此外,cilengitide 显著提高抗程序性细胞死亡蛋白-1免疫治疗疗效,为对抗 PNI 驱动的免疫抑制提供了潜在治疗策略。
本研究确定 ITGA5 是肿瘤侵犯神经的关键促进因子,其增强 Schwann 细胞释放 NGF 并改变免疫格局以利于肿瘤生长。这些发现为针对癌症进展中此类相互作用的治疗开辟了新途径。
Perineural invasion (PNI) complicates cancer treatment by promoting tumor spread and immune evasion through interactions between tumor cells and peripheral nerves in the tumor microenvironment (TME).
This study investigates the role of tumor cells in PNI and their impact on neuro-immunomodulation.
We identified a strong correlation between elevated ITGA5 expression and PNI, both associated with poor clinical outcomes due to their contribution to an immunosuppressive TME. Specifically, high ITGA5 expression in tumor cells increased nerve density and reduced natural killer cell infiltration, facilitating immune evasion.
Functional assays revealed that the interaction between ITGA5 on tumor cells and fibronectin (FN1) in the SC extracellular matrix triggers the reprogramming of SCs to a reparative phenotype, enhancing nerve growth factor (NGF) secretion and promoting tumor neurogenesis. Increased NGF suppresses NK cell cytotoxicity by inhibiting interferon- , further supporting tumor growth.
Additionally, cilengitide significantly improves anti-programmed cell death protein-1 immunotherapy efficacy, offering a potential therapeutic strategy to counteract PNI-driven immunosuppression.
This study identifies ITGA5 as a key promoter of tumor invasion into nerves, enhancing NGF release from Schwann cells and altering the immune landscape to favor tumor growth.
These findings open new avenues for therapies targeting these interactions in cancer progression.
MEMBER ACCOUNT
登录成功会直接打开下一页。